Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (6746)	6/8/1999 2:40:00 PM
From: biowa	Read Replies (1) \| Respond to of 9719

Rick, I think the next public update will be a presentation of the revisited Lilly PII data at ICAAC (which I think will address the endocarditis issue). From what I've seen from papers and posters, the in vitro MIC90 data is better than vancomycin across the board for all Gram positives, and I haven't heard of any significant toxicities. Also, I think it's interesting that the clinical trials include q24h arms. Once daily would be nice for a number of applications (empiric therapy, home infusion therapy, etc.). What have you heard about when we might hear from the PII BSI or PIII SSTI trials? biowa